Drug intelligence / Profile preview

NNC0480-0389

Development stage: Phase 2
Lead developer: Novo Nordisk
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

NNC0480-0389 is a synthetic peptide drug candidate developed by Novo Nordisk for the treatment of type 2 diabetes mellitus and obesity. It is administered subcutaneously. The drug acts as an agonist of the gastric inhibitory polypeptide receptor (GIPR), which plays a role in glucose metabolism and weight regulation. Some sources also suggest it may have activity as a GLP-1 analogue, but its primary mechanism appears to be GIPR agonism. As of early 2025, its highest development phase is Phase 2 for type 2 diabetes mellitus; development for obesity has not progressed beyond discovery or early clinical stages[1][2][3].

Other names: Glucose-dependent insulinotropic polypeptide receptor agonistGIP receptor agonist

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on NNC0480-0389.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0480-0389.

Explore the full profile